Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07281716 · ClinicalTrials.gov registry record · Phase 1
Combination Immunotherapy for the Treatment of Chemotherapy-refractory Metastatic MSS CRC
A Phase 1 study of Metastatic Microsatellite Stable Colorectal Carcinoma, sponsored by Dan Feng.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
- 1
- Study location
NCT07281716 is a Phase 1 study of Metastatic Microsatellite Stable Colorectal Carcinoma that is actively recruiting participants, run by Dan Feng. The registered enrollment target is 24 participants, below the 35-participant average among 6 other Metastatic Microsatellite Stable Colorectal Carcinoma trials with a reported enrollment target (31% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07281716, a Phase 1 study of Metastatic Microsatellite Stable Colorectal Carcinoma, is actively recruiting participants, sponsored by Dan Feng.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
Phase 1b/2 open-label study evaluates the safety, tolerability, and efficacy of combination immunotherapy with nadunolimab (anti-IL-1RAP) and toripalimab (anti-PD-1) in patients with chemotherapy-refractory metastatic microsatellite stable (MSS) colorectal cancer. Phase 1b will assess dose-limiting toxicity (DLT), while Phase 2 will evaluate objective response rate (ORR), including progression-free survival (PFS), overall survival (OS), disease control rate (DCR), and duration of response (DOR). Exploratory analyses will investigate immunomodulatory effects through tumor and peripheral blood studies, and treatment will continue every 3 weeks for up to 1 year or until disease progression.
Conditions Studied
Interventions
- DRUG Toripalimab
- DRUG Nadunolimab
Study Locations (1)
New York
- Icahn School of Medicine at Mount Sinai - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2025-12-01 |
| Est. Completion | 2028-12-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07281716
The ClinicalTrials.gov registry entry for NCT07281716 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 35-participant average among 6 other Metastatic Microsatellite Stable Colorectal Carcinoma trials with a reported enrollment target (31% lower). The listed sponsor is Dan Feng, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Metastatic Microsatellite Stable Colorectal Carcinoma appearing as the primary indexed condition, and to 2 interventions - of which Toripalimab is the first listed.
NCT07281716 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT07281716 about?
NCT07281716 is a clinical study titled "Combination Immunotherapy for the Treatment of Chemotherapy-refractory Metastatic MSS CRC". Phase 1b/2 open-label study evaluates the safety, tolerability, and efficacy of combination immunotherapy with nadunolimab (anti-IL-1RAP) and toripalimab (anti-PD-1) in patients with chemotherapy-refractory metastatic microsatellite stable (MSS) colorectal cancer. Phase 1b will assess dose-limiting ...
What is the current status of trial NCT07281716?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2025-12-01. Estimated completion is 2028-12-15.
What conditions does trial NCT07281716 study?
This clinical trial studies the following conditions: Metastatic Microsatellite Stable Colorectal Carcinoma.
What interventions are being tested in trial NCT07281716?
The interventions under investigation include: Toripalimab (DRUG), Nadunolimab (DRUG).
Who is sponsoring clinical trial NCT07281716?
This trial is sponsored by Dan Feng, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07281716 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Microsatellite Stable Colorectal Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and Effectiveness
RECRUITING · Phase 1
-
Testing the Addition of an Anti-Cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (5-Fluorouracil) for Metastatic, Refractory Colorectal Cancer
RECRUITING · Phase 1
-
FOLFOX and Bevacizumab in Combination With Botensilimab and Balstilimab (3B-FOLFOX) for the Treatment of Microsatellite Stable (MSS) Metastatic Colorectal Cancer
ACTIVE NOT RECRUITING · Phase 1
-
Botensilimab, Balstilimab and Regorafenib for the Treatment of Patients With Microsatellite Stable Metastatic Colorectal Cancer Who Have Progressed on Prior Chemotherapy
ACTIVE NOT RECRUITING · Phase 1
-
Encorafenib, Cetuximab, and Nivolumab in Treating Patients With Microsatellite Stable, BRAFV600E Mutated Unresectable or Metastatic Colorectal Cancer
ACTIVE NOT RECRUITING · Phase 1
-
Niraparib and Panitumumab in Patients With Advanced or Metastatic Colorectal Cancer
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.